Browse by category

Medtimo, a wholly owned subsidiary of Biorad Medisys Private Limited, has filed a patent infringement complaint in the US District Court of the District of Delaware against Allurion Technologies. Medtimo’s complaint claims Allurion's gastric balloon system infringes upon Medtimo's intellectual property. This definitive action follows Allurion’s recent unsuccessful challenge of Medtimo’s patent rights in the US Patent and Trademark Office (USPTO). The complaint alleges that Al

Allurion Technologies has submitted the fourth and final module of the Pre-Market Approval (PMA) application to the FDA and additional,...

Allurion Technologies plans to initiate a clinical study on the combination of the Allurion Program with GLP-1 agonists to improve muscle...

The Agence nationale de sécurité du médicament et des produits de santé (ANSM, National Medicines Safety Agency) in France has suspended...

Allurion has entered a pilot collaboration agreement with Medtronic, to expand access to Allurion’s AI-powered weight loss programme...

Allurion has received approval from the Brazilian Health Regulatory Agency (ANVISA) to launch its Elipse Balloon, the world’s first and...

Allurion has launched its swallowable gastric balloon capsule, the world’s first and only swallowable gastric balloon for weight loss, in...